Italian metallo-beta-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme.

OBJECTIVES As part of the SENTRY Antimicrobial Surveillance Programme, 383 non-replicative randomly collected Pseudomonas aeruginosa isolates were collected during 1999-2002. These strains originated from three geographically distinct hospitals within Italy: Genoa (Northern Italy); Rome and Catania (Sicily), and were further studied to identify the prevalence of metallo-beta-lactamase (MbetaL) alleles across Italy and to determine their genetic details. METHODS Multidrug-resistant (MDR) strains were identified by MIC analysis followed by genotyping and PCR-based strategies. RESULTS Initial MIC analysis identified 31 MDR isolates that displayed an Etest MbetaL-positive phenotype. Of these, 25 produced either the MbetaL VIM-1 or IMP-13 as detected by PCR and sequencing. VIM-1-producing isolates were found at all sites, whereas IMP-13-producing isolates were only found in Rome. MbetaL-producing isolates were found at all Italian SENTRY sites and together amounted to 6.5% of all P. aeruginosa isolates. Genetic analysis indicated that many strains contained multiple integrons and identified two novel MbetaL integrons, one from the site in Genoa and one from Sicily. Integrons identical in structure and sequence to In70, the first identified and characterized bla(VIM)-containing integron from Verona, were found in isolates with distinct ribotypes at the Roman and Sicilian sites indicating that this integron has recently disseminated across Italy. All 25 MbetaL-producing isolates were genetically linked in that all isolates contained Tn5051 sequences and all harboured the insertion sequence IsPa7 which may be involved in the mobilization of these resistance alleles. CONCLUSIONS Taken together, these results indicate that Italy has a nationwide problem of MDR P. aeruginosa produced by mobile MbetaL genes.

[1]  Ronald N. Jones,et al.  First Isolation of blaVIM-2 in Latin America: Report from the SENTRY Antimicrobial Surveillance Program , 2004, Antimicrobial Agents and Chemotherapy.

[2]  Ronald N. Jones,et al.  Pseudomonas aeruginosa strains harbouring an unusual blaVIM-4 gene cassette isolated from hospitalized children in Poland (1998-2001). , 2004, The Journal of antimicrobial chemotherapy.

[3]  C. Bearzi,et al.  Endemic Carbapenem-resistant Pseudomonas aeruginosa with Acquired Metallo-β-lactamase Determinants in European Hospital , 2004, Emerging infectious diseases.

[4]  G. Rossolini,et al.  Emergence in Klebsiella pneumoniae and Enterobacter cloacae Clinical Isolates of the VIM-4 Metallo-β-Lactamase Encoded by a Conjugative Plasmid , 2004, Antimicrobial Agents and Chemotherapy.

[5]  Ronald N. Jones,et al.  bla VIM-7, an Evolutionarily Distinct Metallo-β-Lactamase Gene in a Pseudomonas aeruginosa Isolate from the United States , 2004, Antimicrobial Agents and Chemotherapy.

[6]  G. Rossolini,et al.  Outbreak of multidrug-resistant Pseudomonas aeruginosa producing the metallo beta-lactamase IMP-13 in a general Intensive Care Unit in Southern Italy , 2004 .

[7]  Ronald N. Jones,et al.  Genetic characterization of a novel metallo-beta-lactamase gene, blaIMP-13, harboured by a novel Tn5051-type transposon disseminating carbapenemase genes in Europe: report from the SENTRY worldwide antimicrobial surveillance programme. , 2003, The Journal of antimicrobial chemotherapy.

[8]  V. Miriagou,et al.  Characterization of In111, a class 1 integron that carries the extended-spectrum beta-lactamase gene blaIBC-1. , 2003, FEMS microbiology letters.

[9]  V. Miriagou,et al.  VIM-1 Metallo-β-Lactamase-Producing Klebsiella pneumoniae Strains in Greek Hospitals , 2003, Journal of Clinical Microbiology.

[10]  Ronald N. Jones,et al.  Evolution of an integron carrying blaVIM-2 in Eastern Europe: report from the SENTRY Antimicrobial Surveillance Program. , 2003, The Journal of antimicrobial chemotherapy.

[11]  Y. Chong,et al.  VIM- and IMP-Type Metallo-β-lactamase–Producing Pseudomonas spp. and Acinetobacter spp. in Korean Hospitals , 2003, Emerging infectious diseases.

[12]  G. Rossolini,et al.  IMP-12, a New Plasmid-Encoded Metallo-β-Lactamase from a Pseudomonas putida Clinical Isolate , 2003, Antimicrobial Agents and Chemotherapy.

[13]  D. Mazel,et al.  Comparative analysis of superintegrons: engineering extensive genetic diversity in the Vibrionaceae. , 2003, Genome research.

[14]  M. Castanheira,et al.  Molecular and Biochemical Characterization of a Novel Class B ß-lactamase, GIM-1: a New Subclass of Metallo-ß-Lactamase: Report from the SENTRY Antimicrobial Surveillance Program , 2003 .

[15]  M. Maniati,et al.  Novel Variant (blaVIM-4) of the Metallo-β-Lactamase Gene blaVIM-1 in a Clinical Strain of Pseudomonas aeruginosa , 2002, Antimicrobial Agents and Chemotherapy.

[16]  G. Rossolini,et al.  Nosocomial Infections Caused by Multidrug-Resistant Isolates of Pseudomonas putida Producing VIM-1 Metallo-β-Lactamase , 2002, Journal of Clinical Microbiology.

[17]  Ronald N. Jones,et al.  Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. , 2002, The Journal of antimicrobial chemotherapy.

[18]  P. Nordmann,et al.  Emerging carbapenemases in Gram-negative aerobes. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[19]  P. H. Roy,et al.  Presence of a Group II Intron in a Multiresistant Serratia marcescens Strain That Harbors Three Integrons and a Novel Gene Fusion , 2002, Antimicrobial Agents and Chemotherapy.

[20]  L. Peixe,et al.  Metallo-beta-lactamase VIM-2 in clinical isolates of Pseudomonas aeruginosa from Portugal. , 2002, Microbial drug resistance.

[21]  K. M. Helena Nevalainen,et al.  Gene Cassette PCR: Sequence-Independent Recovery of Entire Genes from Environmental DNA , 2001, Applied and Environmental Microbiology.

[22]  R. Hall,et al.  Family of Class 1 Integrons Related to In4 from Tn1696 , 2001, Antimicrobial Agents and Chemotherapy.

[23]  G. Rossolini,et al.  Molecular heterogeneity of blaVIM-2-containing integrons from Pseudomonas aeruginosa plasmids encoding the VIM-2 metallo-β-lactamase , 2001 .

[24]  L. Pallecchi,et al.  Molecular heterogeneity of bla(VIM-2)-containing integrons from Pseudomonas aeruginosa plasmids encoding the VIM-2 metallo-beta-lactamase. , 2001, FEMS Microbiology Letters.

[25]  N. Woodford,et al.  Carbapenemases: a problem in waiting? , 2000, Current opinion in microbiology.

[26]  G. Cornaglia,et al.  Characterization of the Metallo-β-Lactamase Determinant of Acinetobacter baumannii AC-54/97 Reveals the Existence of blaIMP Allelic Variants Carried by Gene Cassettes of Different Phylogeny , 2000, Antimicrobial Agents and Chemotherapy.

[27]  A. Dalsgaard,et al.  Distribution and Content of Class 1 Integrons in Different Vibrio cholerae O-Serotype Strains Isolated in Thailand , 2000, Antimicrobial Agents and Chemotherapy.

[28]  Thierry Naas,et al.  Characterization of VIM-2, a Carbapenem-Hydrolyzing Metallo-β-Lactamase and Its Plasmid- and Integron-Borne Gene from a Pseudomonas aeruginosa Clinical Isolate in France , 2000, Antimicrobial Agents and Chemotherapy.

[29]  N. Woodford,et al.  Outbreak of Infections Caused by Pseudomonas aeruginosa Producing VIM-1 Carbapenemase in Greece , 2000, Journal of Clinical Microbiology.

[30]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[31]  G. Cornaglia,et al.  Cloning and Characterization of blaVIM, a New Integron-Borne Metallo-β-Lactamase Gene from a Pseudomonas aeruginosa Clinical Isolate , 1999, Antimicrobial Agents and Chemotherapy.

[32]  J. Frère,et al.  Biochemical Characterization of the Pseudomonas aeruginosa 101/1477 Metallo-β-Lactamase IMP-1 Produced byEscherichia coli , 1999, Antimicrobial Agents and Chemotherapy.

[33]  P. Fratamico,et al.  Molecular Characterization of an Antibiotic Resistance Gene Cluster of Salmonella typhimuriumDT104 , 1999, Antimicrobial Agents and Chemotherapy.

[34]  I. Paulsen,et al.  Proton-dependent multidrug efflux systems , 1996, Microbiological reviews.

[35]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.